[ Price : $8.95]
FDA alerts patients and healthcare providers to concerns about compounded semaglutide that is being produced as an alternative to ...[ Price : $8.95]
The CDER Office of Surveillance and Epidemiology 2022 annual report highlights activities in public health emergencies, drug risk ...[ Price : $8.95]
Oncology Center of Excellence director Richard Pazdur explains what FDA can and cant do to address cancer drug shortages.[ Price : $8.95]
Federal Register notice: FDA intends to inactivate the registration of establishments that manufacture human cells, tissues, or ce...[ Price : $8.95]
FDA proposes a regulation to replace the current Medication Guides with a one-page Patient Medication Information sheet.[ Price : $8.95]
FDA warns Woburn, MA-based Advanced Compounding Solutions about multiple violations in its production of unapproved and misbranded...[ Price : $8.95]
FDA accepts for priority review a Bristol Myers Squibb NDA for repotrectinib and its use for treating patients with ROS1-positive ...[ Price : $8.95]
FDA approves Blue Earth Diagnostics Posluma (flotufolastat F 18) injection, a prostate-specific membrane antigen-targeted positron...